Post-earnings recap
Reported
Tue, Nov 4, 2025
EPS actual
$-0.82
EPS est.
$-0.72
EPS surprise
-14.53%
1-day move
-7.69%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Rhythm Pharmaceuticals is struggling with its profitability, as reflected in the negative EPS. The stock's 7.69% decline suggests that investors are reacting negatively to the missed expectations and lack of revenue information. The management's defensive tone indicates ongoing challenges, which may impact investor confidence moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.82 | N/A | -14.53% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed concern over recent performance but remains focused on future strategies. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced this quarter.
They emphasized a commitment to long-term strategies despite current setbacks.